e-learning
resources
Glasgow 2004
Tuesday 07.09.2004
Thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The role of TNF-α and IL-6 in the development of cancer anorexia - cachexia syndrome (CACS) in non-small cell lung cancer (NSCLC)
O. Kayacan, D. Karnak, S. Beder, E. Gullu, D. Koksal, H. Tutkak, F. Cay (Ankara, Turkey)
Source:
Annual Congress 2004 - Thoracic oncology
Session:
Thoracic oncology
Session type:
Poster Discussion
Number:
4104
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Kayacan, D. Karnak, S. Beder, E. Gullu, D. Koksal, H. Tutkak, F. Cay (Ankara, Turkey). The role of TNF-α and IL-6 in the development of cancer anorexia - cachexia syndrome (CACS) in non-small cell lung cancer (NSCLC). Eur Respir J 2004; 24: Suppl. 48, 4104
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Treatment of non-small cell lung cancer (NSCLC) - the state of the art and beyond
Source: International Congress 2017 – State of the art session: "Lung cancer"
Year: 2017
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Is
MIF -173G/C
polymorphism associated with in non-small cell lung cancer (NSCLC) susceptibility?
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010
A novel biologic classification of non-small cell lung cancer
Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Year: 2005
Lung cancer
Source: Respipedia Article
Year: 2018
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
Two-stage treatment of non-small cell lung cancer (NSCLC) in patients with severe coronary heart disease.
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
A non-small cell lung cancer modelling by endogenous κ-ras manipulation
Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection
Year: 2005
Tumour infiltrating lymphocytes and tumour associated macrophages in chronic obstructive pulmonary disease (COPD) patients with non-small cell lung cancer (NSCLC) and in patients with NSCLC
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005
Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002
Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept